The DOI matches its Crossref record; 306 of the 306 references it cites were found in a registry or an index.
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 4.2016
Open accessAbstract
These NCCN Guidelines Insights focus on recent updates in the 2016 NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC; Versions 1-4). These NCCN Guidelines Insights will discuss new immunotherapeutic agents, such as nivolumab and pembrolizumab, for patients with metastatic NSCLC. For the 2016 update, the NCCN panel recommends immune checkpoint inhibitors as preferred agents (in the absence of contraindications) for second-line and beyond (subsequent) therapy in patients with metastatic NSCLC (both squamous and nonsquamous histologies). Nivolumab and pembrolizumab are preferred based on improved overall survival rates, higher response rates, longer duration of response, and fewer adverse events when compared with docetaxel therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Siegel, R. L., Miller, K. D., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21332 · Cited by 16,003
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
SEER Cancer Statistics Review, 1975-2003
Ries, L. A. G., Harkins, D., Krapcho, M. F., Mariotto, A. B., Miller, B., Feuer, E. J., Clegg, L. X., Eisner, M. P., Horner, M., Howlader, N., et al. (2006) · Digital Archive @ GSU · Cited by 11,403
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Self-citationNivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Self-citationGefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer
Temel, J. S., Greer, J. A., Muzikansky, A., Gallagher, E. R., Admane, S., Jackson, V. A., Dahlin, C. M., Blinderman, C. D., Jacobsen, J., Pirl, W. F., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000678 · Cited by 7,482
Cooper, D. S., Doherty, G. M., Haugen, B. R., Kloos, R. T., Lee, S. L., Mandel, S. J., Mazzaferri, E. L., McIver, B., Pacini, F., Schlumberger, M., et al. (2009) · Thyroid · doi:10.1089/thy.2009.0110 · Cited by 6,707
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Self-citationRosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489
Cortazar, P., Zhang, L., Untch, M., Mehta, K., Costantino, J. P., Wolmark, N., Bonnefoi, H., Cameron, D., Gianni, L., Valagussa, P., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62422-8 · Cited by 4,742
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y.-J., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S.-H. I., Dezube, B. J., Jänne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,446
Self-citationWolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2775 · Cited by 4,434
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527
Self-citationFirst-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer
Solomon, B. J., Mok, T., Kim, D.-W., Wu, Y.-L., Nakagawa, K., Mekhail, T., Felip, E., Cappuzzo, F., Paolini, J., Usari, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408440 · Cited by 3,190
Liedtke, C., Mazouni, C., Hess, K. R., André, F., Tordai, A., Mejia, J. A., Symmans, W. F., Gonzalez-Angulo, A. M., Hennessy, B., Green, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.4147 · Cited by 2,892
Immune Checkpoint Blockade in Cancer Therapy
Postow, M. A., Callahan, M. K., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4358 · Cited by 2,709
von Minckwitz, G., Untch, M., Blohmer, J.-U., Costa, S. D., Eidtmann, H., Fasching, P. A., Gerber, B., Eiermann, W., Hilfrich, J., Huober, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.8595 · Cited by 2,659
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
Armstrong, D. K., Bundy, B., Wenzel, L., Huang, H. Q., Baergen, R., Lele, S., Copeland, L. J., Walker, J. L., & Burger, R. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052985 · Cited by 2,625
Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
Vergote, I., Tropé, C. G., Amant, F., Kristensen, G. B., Ehlen, T., Johnson, N., Verheijen, R. H. M., van der Burg, M. E. L., Lacave, A. J., Panici, P. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908806 · Cited by 2,537
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Baselga, J., Cortés, J., Kim, S.-B., Im, S.-A., Hegg, R., Im, Y.-H., Roman, L., Pedrini, J. L., Pienkowski, T., Knott, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113216 · Cited by 2,532
Sternberg, C. N., Davis, I. D., Mardiak, J., Szczylik, C., Lee, E., Wagstaff, J., Barrios, C. H., Salman, P., Gladkov, O. A., Kavina, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.9764 · Cited by 2,471
Yu, H. A., Arcila, M. E., Rekhtman, N., Sima, C. S., Zakowski, M. F., Pao, W., Kris, M. G., Miller, V. A., Ladanyi, M., & Riely, G. J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2246 · Cited by 2,454
Self-citationIncorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Burger, R. A., Brady, M. F., Bookman, M. A., Fleming, G. F., Monk, B. J., Huang, H., Mannel, R. S., Homesley, H. D., Fowler, J., Greer, B. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104390 · Cited by 2,404
Gianni, L., Pienkowski, T., Im, Y.-H., Roman, L., Tseng, L.-M., Liu, M.-C., Lluch, A., Staroslawska, E., de la Haba-Rodriguez, J., Im, S.-A., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70336-9 · Cited by 2,374
Sampson, H. A., Muñoz-Furlong, A., Campbell, R. L., Adkinson, N. F., Bock, S. A., Branum, A., Brown, S. G. A., Camargo, C. A., Cydulka, R., Galli, S. J., et al. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.12.1303 · Cited by 2,313
Bristow, R. E., Tomacruz, R. S., Armstrong, D. K., Trimble, E. L., & Montz, F. J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.5.1248 · Cited by 2,312
A Phase 3 Trial of Bevacizumab in Ovarian Cancer
Perren, T. J., Swart, A. M., Pfisterer, J., Ledermann, J. A., Pujade-Lauraine, E., Kristensen, G., Carey, M. S., Beale, P., Cervantes, A., Kurzeder, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103799 · Cited by 2,172
Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
Schlumberger, M., Tahara, M., Wirth, L. J., Robinson, B., Brose, M. S., Elisei, R., Habra, M. A., Newbold, K., Shah, M. H., Hoff, A. O., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1406470 · Cited by 2,096
Ozols, R. F., Bundy, B. N., Greer, B. E., Fowler, J. M., Clarke-Pearson, D., Burger, R. A., Mannel, R. S., DeGeest, K., Hartenbach, E. M., & Baergen, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.153 · Cited by 2,032
Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
Ledermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., Scott, C., Meier, W., Shapira-Frommer, R., Safra, T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105535 · Cited by 1,883
Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
Shaw, A. T., Yeap, B. Y., Mino-Kenudson, M., Digumarthy, S. R., Costa, D. B., Heist, R. S., Solomon, B., Stubbs, H., Admane, S., McDermott, U., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.6993 · Cited by 1,870
Self-citationEarly palliative care for patients with advanced cancer: a cluster-randomised controlled trial
Zimmermann, C., Swami, N., Krzyzanowska, M., Hannon, B., Leighl, N., Oza, A., Moore, M., Rydall, A., Rodin, G., Tannock, I., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62416-2 · Cited by 1,781
Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
Kris, M. G., Johnson, B. E., Berry, L. D., Kwiatkowski, D. J., Iafrate, A. J., Wistuba, I. I., Varella-Garcia, M., Franklin, W. A., Aronson, S. L., Su, P.-F., et al. (2014) · JAMA · doi:10.1001/jama.2014.3741 · Cited by 1,724
Self-citationBrose, M. S., Nutting, C. M., Jarzab, B., Elisei, R., Siena, S., Bastholt, L., de la Fouchardiere, C., Pacini, F., Paschke, R., Shong, Y. K., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60421-9 · Cited by 1,663
Palbociclib in hormone-receptor-positive advanced breast cancer
Turner, N. C., Ro, J., André, F., Loi, S., Verma, S., Iwata, H., Harbeck, N., Loibl, S., Huang Bartlett, C., Zhang, K., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505270 · Cited by 1,590
Fukuoka, M., Wu, Y.-L., Thongprasert, S., Sunpaweravong, P., Leong, S.-S., Sriuranpong, V., Chao, T.-Y., Nakagawa, K., Chu, D.-T., Saijo, N., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.4235 · Cited by 1,581
Yang, J. C.-H., Wu, Y.-L., Schuler, M., Sebastian, M., Popat, S., Yamamoto, N., Zhou, C., Hu, C.-P., O'Byrne, K., Feng, J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71173-8 · Cited by 1,574
Wells, S. A., Robinson, B. G., Gagel, R. F., Dralle, H., Fagin, J. A., Santoro, M., Baudin, E., Elisei, R., Jarzab, B., Vasselli, J. R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.5040 · Cited by 1,559
ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
Bergethon, K., Shaw, A. T., Ignatius Ou, S.-H., Katayama, R., Lovly, C. M., McDonald, N. T., Massion, P. P., Siwak-Tapp, C., Gonzalez, A., Fang, R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.6345 · Cited by 1,555
Hegedüs, L. (2004) · New England Journal of Medicine · doi:10.1056/nejmcp031436 · Cited by 1,502
Rizvi, N. A., Mazières, J., Planchard, D., Stinchcombe, T. E., Dy, G. K., Antonia, S. J., Horn, L., Lena, H., Minenza, E., Mennecier, B., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70054-9 · Cited by 1,415
Self-citationManagement of a Solitary Thyroid Nodule
Desforges, J. F., & Mazzaferri, E. L. (1993) · New England Journal of Medicine · doi:10.1056/nejm199302253280807 · Cited by 1,412
Nikiforov, Y. E., Seethala, R. R., Tallini, G., Baloch, Z. W., Basolo, F., Thompson, L. D. R., Barletta, J. A., Wenig, B. M., Al Ghuzlan, A., Kakudo, K., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.0386 · Cited by 1,404
Aghajanian, C., Blank, S. V., Goff, B. A., Judson, P. L., Teneriello, M. G., Husain, A., Sovak, M. A., Yi, J., & Nycum, L. R. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.0505 · Cited by 1,384
Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas
Younes, A., Bartlett, N. L., Leonard, J. P., Kennedy, D. A., Lynch, C. M., Sievers, E. L., & Forero-Torres, A. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002965 · Cited by 1,368
Medullary Thyroid Cancer: Management Guidelines of the American Thyroid Association
Kloos (Chair), R. T., Eng, C., Evans, D. B., Francis, G. L., Gagel, R. F., Gharib, H., Moley, J. F., Pacini, F., Ringel, M. D., Schlumberger, M., et al. (2009) · Thyroid · doi:10.1089/thy.2008.0403 · Cited by 1,357
Buys, S. S. (2011) · JAMA · doi:10.1001/jama.2011.766 · Cited by 1,323
Lindeman, N. I., Cagle, P. T., Beasley, M. B., Chitale, D. A., Dacic, S., Giaccone, G., Jenkins, R. B., Kwiatkowski, D. J., Saldivar, J.-S., Squire, J., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318290868f · Cited by 1,280
Camidge, D. R., Bang, Y.-J., Kwak, E. L., Iafrate, A. J., Varella-Garcia, M., Fox, S. B., Riely, G. J., Solomon, B., Ou, S.-H. I., Kim, D.-W., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70344-3 · Cited by 1,268
Self-citationSchneeweiss, A., Chia, S., Hickish, T., Harvey, V., Eniu, A., Hegg, R., Tausch, C., Seo, J. H., Tsai, Y.-F., Ratnayake, J., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt182 · Cited by 1,264
Henry, D. H., Costa, L., Goldwasser, F., Hirsh, V., Hungria, V., Prausova, J., Scagliotti, G. V., Sleeboom, H., Spencer, A., Vadhan-Raj, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.3304 · Cited by 1,263
Alberts, D. S., Liu, P. Y., Hannigan, E. V., O'Toole, R., Williams, S. D., Young, J. A., Franklin, E. W., Clarke-Pearson, D. L., Malviya, V. K., DuBeshter, B., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199612263352603 · Cited by 1,228
Cabozantinib in Progressive Medullary Thyroid Cancer
Elisei, R., Schlumberger, M. J., Müller, S. P., Schöffski, P., Brose, M. S., Shah, M. H., Licitra, L., Jarzab, B., Medvedev, V., Kreissl, M. C., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.4659 · Cited by 1,217
Neoadjuvant Versus Adjuvant Systemic Treatment in Breast Cancer: A Meta-Analysis
Mauri, D., Pavlidis, N., & Ioannidis, J. P. A. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji021 · Cited by 1,200
Gettinger, S. N., Horn, L., Gandhi, L., Spigel, D. R., Antonia, S. J., Rizvi, N. A., Powderly, J. D., Heist, R. S., Carvajal, R. D., Jackman, D. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.3708 · Cited by 1,177
Self-citationPreoperative Diagnosis of Benign Thyroid Nodules with Indeterminate Cytology
Alexander, E. K., Kennedy, G. C., Baloch, Z. W., Cibas, E. S., Chudova, D., Diggans, J., Friedman, L., Kloos, R. T., LiVolsi, V. A., Mandel, S. J., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203208 · Cited by 1,163
Patients’ expectations about effects of chemotherapy for advanced cancer
Weeks, J. C., Catalano, P. J., Cronin, A., Finkelman, M. D., Mack, J. W., Keating, N. L., & Schrag, D. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1204410 · Cited by 1,149
Schmitz, N., Pfistner, B., Sextro, M., Sieber, M., Carella, A. M., Haenel, M., Boissevain, F., Zschaber, R., Müller, P., Kirchner, H., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08938-9 · Cited by 1,140
Linch, D. C., Goldstone, A. H., McMillan, A., Chopra, R., Vaughan Hudson, G., Winfield, D., Hancock, B., Moir, D., & Milligan, D. (1993) · The Lancet · doi:10.1016/0140-6736(93)92411-l · Cited by 1,051
American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer
Smallridge, R. C., Ain, K. B., Asa, S. L., Bible, K. C., Brierley, J. D., Burman, K. D., Kebebew, E., Lee, N. Y., Nikiforov, Y. E., Rosenthal, M. S., et al. (2012) · Thyroid · doi:10.1089/thy.2012.0302 · Cited by 935
Reduced Treatment Intensity in Patients with Early-Stage Hodgkin's Lymphoma
Engert, A., Plütschow, A., Eich, H. T., Lohri, A., Dörken, B., Borchmann, P., Berger, B., Greil, R., Willborn, K. C., Wilhelm, M., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000067 · Cited by 928
Pseudoprogression and Immune-Related Response in Solid Tumors
Chiou, V. L., & Burotto, M. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.6870 · Cited by 903
Subbiah, V., Kreitman, R. J., Wainberg, Z. A., Cho, J. Y., Schellens, J. H. M., Soria, J. C., Wen, P. Y., Zielinski, C., Cabanillas, M. E., Urbanowitz, G., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.6785 · Cited by 892
Burger, R. A., Sill, M. W., Monk, B. J., Greer, B. E., & Sorosky, J. I. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.5345 · Cited by 882
Gallamini, A., Hutchings, M., Rigacci, L., Specht, L., Merli, F., Hansen, M., Patti, C., Loft, A., Di Raimondo, F., D'Amore, F., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.6525 · Cited by 846
Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer
Ho, A. L., Grewal, R. K., Leboeuf, R., Sherman, E. J., Pfister, D. G., Deandreis, D., Pentlow, K. S., Zanzonico, P. B., Haque, S., Gavane, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209288 · Cited by 843
Menon, U., Gentry-Maharaj, A., Hallett, R., Ryan, A., Burnell, M., Sharma, A., Lewis, S., Davies, S., Philpott, S., Lopes, A., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70026-9 · Cited by 829
Wright, A. A., Keating, N. L., Balboni, T. A., Matulonis, U. A., Block, S. D., & Prigerson, H. G. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3863 · Cited by 797
Nikiforov, Y. E., Ohori, N. P., Hodak, S. P., Carty, S. E., LeBeau, S. O., Ferris, R. L., Yip, L., Seethala, R. R., Tublin, M. E., Stang, M. T., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1469 · Cited by 790
Gomes, B., Calanzani, N., Curiale, V., McCrone, P., Higginson, I. J., & de Brito, M. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007760.pub2 · Cited by 785
Smith, I. E., Dowsett, M., Ebbs, S. R., Dixon, J. M., Skene, A., Blohmer, J.-U., Ashley, S. E., Francis, S., Boeddinghaus, I., & Walsh, G. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.005 · Cited by 774
Cannistra, S. A., Matulonis, U. A., Penson, R. T., Hambleton, J., Dupont, J., Mackey, H., Douglas, J., Burger, R. A., Armstrong, D., Wenham, R., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.0782 · Cited by 759
Dawood, S., Broglio, K., Buzdar, A. U., Hortobagyi, G. N., & Giordano, S. H. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.9844 · Cited by 758
Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer
Pagani, O., Regan, M. M., Walley, B. A., Fleming, G. F., Colleoni, M., Láng, I., Gomez, H. L., Tondini, C., Burstein, H. J., Perez, E. A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1404037 · Cited by 749
Katsumata, N., Yasuda, M., Takahashi, F., Isonishi, S., Jobo, T., Aoki, D., Tsuda, H., Sugiyama, T., Kodama, S., Kimura, E., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61157-0 · Cited by 727
Hutchings, M., Loft, A., Hansen, M., Pedersen, L. M., Buhl, T., Jurlander, J., Buus, S., Keiding, S., D'Amore, F., Boesen, A.-M., et al. (2006) · Blood · doi:10.1182/blood-2005-06-2252 · Cited by 726
Adjuvant Ovarian Suppression in Premenopausal Breast Cancer
Francis, P. A., Regan, M. M., Fleming, G. F., Láng, I., Ciruelos, E., Bellet, M., Bonnefoi, H. R., Climent, M. A., Da Prada, G. A., Burstein, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412379 · Cited by 726
Eiermann, W., Paepke, S., Appfelstaedt, J., Llombart-Cussac, A., Eremin, J., Vinholes, J., Mauriac, L., Ellis, M., Lassus, M., Chaudri-Ross, H. A., et al. (2001) · Annals of Oncology · doi:10.1023/a:1013128213451 · Cited by 713
Molecular Testing for Mutations in Improving the Fine-Needle Aspiration Diagnosis of Thyroid Nodules
Nikiforov, Y. E., Steward, D. L., Robinson-Smith, T. M., Haugen, B. R., Klopper, J. P., Zhu, Z., Fagin, J. A., Falciglia, M., Weber, K., & Nikiforova, M. N. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0247 · Cited by 711
Rosen, L. S., Gordon, D., Tchekmedyian, N. S., Yanagihara, R., Hirsh, V., Krzakowski, M., Pawlicki, M., de Souza, P., Zheng, M., Urbanowitz, G., et al. (2004) · Cancer · doi:10.1002/cncr.20308 · Cited by 705
Temel, J. S., Greer, J. A., Admane, S., Gallagher, E. R., Jackson, V. A., Lynch, T. J., Lennes, I. T., Dahlin, C. M., & Pirl, W. F. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.4459 · Cited by 696
Yang, J., Schnadig, V., Logrono, R., & Wasserman, P. G. (2007) · Cancer · doi:10.1002/cncr.22955 · Cited by 685
Phase II Trial of Sorafenib in Advanced Thyroid Cancer
Gupta-Abramson, V., Troxel, A. B., Nellore, A., Puttaswamy, K., Redlinger, M., Ransone, K., Mandel, S. J., Flaherty, K. T., Loevner, L. A., O'Dwyer, P. J., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.3279 · Cited by 680
Rodig, S. J., Mino-Kenudson, M., Dacic, S., Yeap, B. Y., Shaw, A., Barletta, J. A., Stubbs, H., Law, K., Lindeman, N., Mark, E., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0802 · Cited by 678
Self-citationCancer Pain Relief and Palliative Care: Report of a WHO Expert Committee
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-8-712_4 · Cited by 646
Vasey, P. A., Jayson, G. C., Gordon, A., Gabra, H., Coleman, R., Atkinson, R., Parkin, D., Paul, J., Hay, A., Kaye, S. B., et al. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh323 · Cited by 632
Cohen, E. E. W., Rosen, L. S., Vokes, E. E., Kies, M. S., Forastiere, A. A., Worden, F. P., Kane, M. A., Sherman, E., Kim, S., Bycott, P., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.9566 · Cited by 623
Yasuda, H., Kobayashi, S., & Costa, D. B. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70129-2 · Cited by 610
Castells, M. C., Tennant, N. M., Sloane, D. E., Ida Hsu, F., Barrett, N. A., Hong, D. I., Laidlaw, T. M., Legere, H. J., Nallamshetty, S. N., Palis, R. I., et al. (2008) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2008.02.044 · Cited by 600
Kosaka, T., Yatabe, Y., Endoh, H., Yoshida, K., Hida, T., Tsuboi, M., Tada, H., Kuwano, H., & Mitsudomi, T. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0714 · Cited by 589
Communicating with realism and hope: incurable cancer patients' views on the disclosure of prognosis
Hagerty, R. G., Butow, P. N., Ellis, P. M., Lobb, E. A., Pendlebury, S. C., Leighl, N., Mac Leod, C., & Tattersall, M. H. N. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.11.138 · Cited by 582
van der Burg, M. E. L., van Lent, M., Buyse, M., Kobierska, A., Colombo, N., Favalli, G., Lacave, A. J., Nardi, M., Renard, J., & Pecorelli, S. (1995) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-199507000-00012 · Cited by 578
Progress in molecular-based management of differentiated thyroid cancer
Xing, M., Haugen, B. R., & Schlumberger, M. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60109-9 · Cited by 573
Yasuda, H., Park, E., Yun, C.-H., Sng, N. J., Lucena-Araujo, A. R., Yeo, W.-L., Huberman, M. S., Cohen, D. W., Nakayama, S., Ishioka, K., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007205 · Cited by 571
Self-citationDrapkin, R., von Horsten, H. H., Lin, Y., Mok, S. C., Crum, C. P., Welch, W. R., & Hecht, J. L. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3924 · Cited by 570
The Histologic Type and Stage Distribution of Ovarian Carcinomas of Surface Epithelial Origin
Seidman, J. D., Horkayne-Szakaly, I., Haiba, M., Boice, C. R., Kurman, R. J., & Ronnett, B. M. (2004) · International Journal of Gynecological Pathology · doi:10.1097/01.pgp.0000101080.35393.16 · Cited by 554
Ellis, M. J., Suman, V. J., Hoog, J., Lin, L., Snider, J., Prat, A., Parker, J. S., Luo, J., DeSchryver, K., Allred, D. C., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.6950 · Cited by 551
Kurzrock, R., Sherman, S. I., Ball, D. W., Forastiere, A. A., Cohen, R. B., Mehra, R., Pfister, D. G., Cohen, E. E. W., Janisch, L., Nauling, F., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.4145 · Cited by 550
Phase II Trial of Sorafenib in Metastatic Thyroid Cancer
Kloos, R. T., Ringel, M. D., Knopp, M. V., Hall, N. C., King, M., Stevens, R., Liang, J., Wakely, P. E., Vasko, V. V., Saji, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.2717 · Cited by 541
Peppercorn, J. M., Smith, T. J., Helft, P. R., DeBono, D. J., Berry, S. R., Wollins, D. S., Hayes, D. M., Von Roenn, J. H., & Schnipper, L. E. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.1744 · Cited by 524
Li, T., Kung, H.-J., Mack, P. C., & Gandara, D. R. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.3753 · Cited by 518
Cancer Patient Preferences for Communication of Prognosis in the Metastatic Setting
Hagerty, R. G., Butow, P. N., Ellis, P. A., Lobb, E. A., Pendlebury, S., Leighl, N., Goldstein, D., Lo, S. K., & Tattersall, M. H. N. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.095 · Cited by 503
McCluggage, W. G. (2011) · Pathology · doi:10.1097/pat.0b013e328348a6e7 · Cited by 497
Griggs, J. J., Mangu, P. B., Anderson, H., Balaban, E. P., Dignam, J. J., Hryniuk, W. M., Morrison, V. A., Pini, T. M., Runowicz, C. D., Rosner, G. L., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.9436 · Cited by 485
Arcila, M. E., Nafa, K., Chaft, J. E., Rekhtman, N., Lau, C., Reva, B. A., Zakowski, M. F., Kris, M. G., & Ladanyi, M. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0620 · Cited by 473
Response to Cabozantinib in Patients with RET Fusion-Positive Lung Adenocarcinomas
Drilon, A., Wang, L., Hasanovic, A., Suehara, Y., Lipson, D., Stephens, P., Ross, J., Miller, V., Ginsberg, M., Zakowski, M. F., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0035 · Cited by 464
Pegylated Liposomal Doxorubicin: Metamorphosis of an Old Drug into a New Form of Chemotherapy
Gabizon, A. A. (2001) · Cancer Investigation · doi:10.1081/cnv-100103136 · Cited by 458
Thyroid Incidentalomas: Prevalence by Palpation and Ultrasonography
Ezzat, S. (1994) · Archives of Internal Medicine · doi:10.1001/archinte.1994.00420160075010 · Cited by 454
Salani, R., Backes, F. J., Fung Kee Fung, M., Holschneider, C. H., Parker, L. P., Bristow, R. E., & Goff, B. A. (2011) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2011.03.008 · Cited by 428
Mutch, D. G., Orlando, M., Goss, T., Teneriello, M. G., Gordon, A. N., McMeekin, S. D., Wang, Y., Scribner, D. R., Marciniack, M., Naumann, R. W., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6735 · Cited by 426
Gordon, A. N., Tonda, M., Sun, S., & Rackoff, W. (2004) · Gynecologic Oncology · doi:10.1016/j.ygyno.2004.07.011 · Cited by 422
Shi, Y., Zhang, L., Liu, X., Zhou, C., Zhang, L., Zhang, S., Wang, D., Li, Q., Qin, S., Hu, C., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70355-3 · Cited by 422
Carr, L. L., Mankoff, D. A., Goulart, B. H., Eaton, K. D., Capell, P. T., Kell, E. M., Bauman, J. E., & Martins, R. G. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0994 · Cited by 422
Self-citationBible, K. C., Suman, V. J., Molina, J. R., Smallridge, R. C., Maples, W. J., Menefee, M. E., Rubin, J., Sideras, K., Morris, J. C., McIver, B., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70203-5 · Cited by 421
End-of-Life Care Discussions Among Patients With Advanced Cancer: A Cohort Study
Mack, J. W., Cronin, A., Taback, N., Huskamp, H. A., Keating, N. L., Malin, J. L., Earle, C. C., & Weeks, J. C. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-3-201202070-00008 · Cited by 420
Follicular variant of papillary thyroid carcinoma: A clinicopathologic study of a problematic entity
Liu, J., Singh, B., Tallini, G., Carlson, D. L., Katabi, N., Shaha, A., Tuttle, R. M., & Ghossein, R. A. (2006) · Cancer · doi:10.1002/cncr.22138 · Cited by 416
ABVD Alone versus Radiation-Based Therapy in Limited-Stage Hodgkin's Lymphoma
Meyer, R. M., Gospodarowicz, M. K., Connors, J. M., Pearcey, R. G., Wells, W. A., Winter, J. N., Horning, S. J., Dar, A. R., Shustik, C., Stewart, D. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1111961 · Cited by 406
Managing Immune Checkpoint-Blocking Antibody Side Effects
Postow, M. A. (2015) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2015.35.76 · Cited by 403
Clarke-Pearson, D. L. (2009) · New England Journal of Medicine · doi:10.1056/nejmcp0901926 · Cited by 400
Gralow, J. R., Burstein, H. J., Wood, W., Hortobagyi, G. N., Gianni, L., von Minckwitz, G., Buzdar, A. U., Smith, I. E., Symmans, W. F., Singh, B., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.3510 · Cited by 400
Differences in Tumor Type in Low-stage Versus High-stage Ovarian Carcinomas
Köbel, M., Kalloger, S. E., Huntsman, D. G., Santos, J. L., Swenerton, K. D., Seidman, J. D., & Gilks, C. B. (2010) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0b013e3181c042b6 · Cited by 398
Ferris, F. D., Bruera, E., Cherny, N., Cummings, C., Currow, D., Dudgeon, D., JanJan, N., Strasser, F., von Gunten, C. F., & Von Roenn, J. H. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.1558 · Cited by 396
Brose, M. S., Cabanillas, M. E., Cohen, E. E. W., Wirth, L. J., Riehl, T., Yue, H., Sherman, S. I., & Sherman, E. J. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30166-8 · Cited by 388
Rivera, M., Ricarte-Filho, J., Knauf, J., Shaha, A., Tuttle, M., Fagin, J. A., & Ghossein, R. A. (2010) · Modern Pathology · doi:10.1038/modpathol.2010.112 · Cited by 386
Phase II Clinical Trial of Sorafenib in Metastatic Medullary Thyroid Cancer
Lam, E. T., Ringel, M. D., Kloos, R. T., Prior, T. W., Knopp, M. V., Liang, J., Sammet, S., Hall, N. C., Wakely, P. E., Vasko, V. V., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.0068 · Cited by 377
Rothenberg, S. M., McFadden, D. G., Palmer, E. L., Daniels, G. H., & Wirth, L. J. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2915 · Cited by 376
General considerations on rapid desensitization for drug hypersensitivity – a consensus statement
Cernadas, J. R., Brockow, K., Romano, A., Aberer, W., Torres, M. J., Bircher, A., Campi, P., Sanz, M. L., Castells, M., Demoly, P., et al. (2010) · Allergy · doi:10.1111/j.1398-9995.2010.02441.x · Cited by 375
Mazières, J., Zalcman, G., Crinò, L., Biondani, P., Barlesi, F., Filleron, T., Dingemans, A.-M. C., Léna, H., Monnet, I., Rothschild, S. I., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.3302 · Cited by 369
A Large Multicenter Correlation Study of Thyroid Nodule Cytopathology and Histopathology
Wang, C.-C. C., Friedman, L., Kennedy, G. C., Wang, H., Kebebew, E., Steward, D. L., Zeiger, M. A., Westra, W. H., Wang, Y., Khanafshar, E., et al. (2011) · Thyroid · doi:10.1089/thy.2010.0243 · Cited by 362
Natural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 20 Insertions
Oxnard, G. R., Lo, P. C., Nishino, M., Dahlberg, S. E., Lindeman, N. I., Butaney, M., Jackman, D. M., Johnson, B. E., & Jänne, P. A. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182779d18 · Cited by 360
Update on Epidermal Growth Factor Receptor Mutations in Non–Small Cell Lung Cancer
Riely, G. J., Politi, K. A., Miller, V. A., & Pao, W. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0658 · Cited by 360
Self-citationVan Gorp, T., Cadron, I., Despierre, E., Daemen, A., Leunen, K., Amant, F., Timmerman, D., De Moor, B., & Vergote, I. (2011) · British Journal of Cancer · doi:10.1038/sj.bjc.6606092 · Cited by 354
Cataliotti, L., Buzdar, A. U., Noguchi, S., Bines, J., Takatsuka, Y., Petrakova, K., Dube, P., & Tosello de Oliveira, C. (2006) · Cancer · doi:10.1002/cncr.21872 · Cited by 352
Emerging Paradigms in the Development of Resistance to Tyrosine Kinase Inhibitors in Lung Cancer
Gainor, J. F., & Shaw, A. T. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.2029 · Cited by 346
Camidge, D. R., Kono, S. A., Flacco, A., Tan, A.-C., Doebele, R. C., Zhou, Q., Crino, L., Franklin, W. A., & Varella-Garcia, M. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0851 · Cited by 341
Self-citationPrognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma
Hutchings, M., Mikhaeel, N. G., Fields, P. A., Nunan, T., & Timothy, A. R. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi200 · Cited by 327
Meyer, R. M., Gospodarowicz, M. K., Connors, J. M., Pearcey, R. G., Bezjak, A., Wells, W. A., Burns, B. F., Winter, J. N., Horning, S. J., Dar, A. R., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.085 · Cited by 323
New insights into ovarian cancer pathology
Prat, J. (2012) · Annals of Oncology · doi:10.1093/annonc/mds300 · Cited by 317
Cleeland, C. S., Zhao, F., Chang, V. T., Sloan, J. A., O'Mara, A. M., Gilman, P. B., Weiss, M., Mendoza, T. R., Lee, J., & Fisch, M. J. (2013) · Cancer · doi:10.1002/cncr.28376 · Cited by 316
Factors Important to Patients' Quality of Life at the End of Life
Zhang, B., Nilsson, M. E., & Prigerson, H. G. (2012) · Archives of Internal Medicine · doi:10.1001/archinternmed.2012.2364 · Cited by 308
Rosell, R., Molina, M. A., Costa, C., Simonetti, S., Gimenez-Capitan, A., Bertran-Alamillo, J., Mayo, C., Moran, T., Mendez, P., Cardenal, F., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2158 · Cited by 304
Oncologist Burnout: Causes, Consequences, and Responses
Shanafelt, T., & Dyrbye, L. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.7380 · Cited by 304
D'Angelo, S. P., Pietanza, M. C., Johnson, M. L., Riely, G. J., Miller, V. A., Sima, C. S., Zakowski, M. F., Rusch, V. W., Ladanyi, M., & Kris, M. G. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.6181 · Cited by 301
Self-citationEberhard, D. A., Giaccone, G., & Johnson, B. E. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.9858 · Cited by 300
Cramer, D. W., Bast, R. C., Berg, C. D., Diamandis, E. P., Godwin, A. K., Hartge, P., Lokshin, A. E., Lu, K. H., McIntosh, M. W., Mor, G., et al. (2011) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0195 · Cited by 300
Liu, R., Bishop, J., Zhu, G., Zhang, T., Ladenson, P. W., & Xing, M. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.3288 · Cited by 296
Gallamini, A., Rigacci, L., Merli, F., Nassi, L., Bosi, A., Capodanno, I., Luminari, S., Vitolo, U., Sancetta, R., D, E. I. M., et al. (2006) · PubMed · Cited by 293
Referral Practices of Oncologists to Specialized Palliative Care
Wentlandt, K., Krzyzanowska, M. K., Swami, N., Rodin, G. M., Le, L. W., & Zimmermann, C. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.0248 · Cited by 286
Leighl, N. B., Rekhtman, N., Biermann, W. A., Huang, J., Mino-Kenudson, M., Ramalingam, S. S., West, H., Whitlock, S., & Somerfield, M. R. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.3055 · Cited by 281
Role of Functional Imaging in the Management of Lymphoma
Cheson, B. D. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.5225 · Cited by 280
Dennis, S., Musa, F., Dao, F., Zivanovic, O., Sonoda, Y., Leitão, M. M., Levine, D. A., Gardner, G. J., Abu‐Rustum, N. R., & Barakat, R. R. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.08.014 · Cited by 277
Li, C., Lee, K. C., Schneider, E. B., & Zeiger, M. A. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2104 · Cited by 275
Molecular Classification of Thyroid Nodules Using High-Dimensionality Genomic Data
Chudova, D., Wilde, J. I., Wang, E. T., Wang, H., Rabbee, N., Egidio, C. M., Reynolds, J., Tom, E., Pagan, M., Rigl, C. T., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1087 · Cited by 274
Kelly, L. M., Barila, G., Liu, P., Evdokimova, V. N., Trivedi, S., Panebianco, F., Gandhi, M., Carty, S. E., Hodak, S. P., Luo, J., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1321937111 · Cited by 271
Robinson, B. G., Paz-Ares, L., Krebs, A., Vasselli, J., & Haddad, R. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2461 · Cited by 257
Ohori, N. P., Nikiforova, M. N., Schoedel, K. E., LeBeau, S. O., Hodak, S. P., Seethala, R. R., Carty, S. E., Ogilvie, J. B., Yip, L., & Nikiforov, Y. E. (2010) · Cancer Cytopathology · doi:10.1002/cncy.20063 · Cited by 254
Terasawa, T., Lau, J., Bardet, S., Couturier, O., Hotta, T., Hutchings, M., Nihashi, T., & Nagai, H. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.0861 · Cited by 254
Han, S.-W., Kim, T.-Y., Jeon, Y. K., Hwang, P. G., Im, S.-A., Lee, K.-H., Kim, J. H., Kim, D.-W., Heo, D. S., Kim, N. K., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2845 · Cited by 253
Releasing the Brakes on Cancer Immunotherapy
Ribas, A. (2015) · New England Journal of Medicine · doi:10.1056/nejmp1510079 · Cited by 252
Besse, B., Adjei, A., Baas, P., Meldgaard, P., Nicolson, M., Paz-Ares, L., Reck, M., Smit, E. F., Syrigos, K., Stahel, R., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu123 · Cited by 244
Hoftijzer, H., Heemstra, K. A., Morreau, H., Stokkel, M. P., Corssmit, E. P., Gelderblom, H., Weijers, K., Pereira, A. M., Huijberts, M., Kapiteijn, E., et al. (2009) · European Journal of Endocrinology · doi:10.1530/eje-09-0702 · Cited by 242
El‐Jawahri, A., Traeger, L., Park, E. R., Greer, J. A., Pirl, W. F., Lennes, I. T., Jackson, V. A., Gallagher, E. R., & Temel, J. S. (2014) · Cancer · doi:10.1002/cncr.28369 · Cited by 240
Palliative Care Inpatient Service in a Comprehensive Cancer Center: Clinical and Financial Outcomes
Elsayem, A., Swint, K., Fisch, M. J., Palmer, J. L., Reddy, S., Walker, P., Zhukovsky, D., Knight, P., & Bruera, E. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.003 · Cited by 234
KRAS Mutation: Should We Test for It, and Does It Matter?
Roberts, P. J., & Stinchcombe, T. E. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.0454 · Cited by 228
BRAF Inhibitor Dabrafenib in Patients with Metastatic BRAF -Mutant Thyroid Cancer
Falchook, G. S., Millward, M., Hong, D., Naing, A., Piha-Paul, S., Waguespack, S. G., Cabanillas, M. E., Sherman, S. I., Ma, B., Curtis, M., et al. (2015) · Thyroid · doi:10.1089/thy.2014.0123 · Cited by 227
Khoja, L., Butler, M. O., Kang, S. P., Ebbinghaus, S., & Joshua, A. M. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0078-9 · Cited by 225
Compassion Fatigue: A Review of the Research to Date and Relevance to Cancer-care Providers
Najjar, N., Davis, L. W., Beck-Coon, K., & Carney Doebbeling, C. (2009) · Journal of Health Psychology · doi:10.1177/1359105308100211 · Cited by 221
Recent Clinical Advances in Lung Cancer Management
Johnson, D. H., Schiller, J. H., & Bunn, P. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.1228 · Cited by 221
McIver, B., Castro, M. R., Morris, J. C., Bernet, V., Smallridge, R., Henry, M., Kosok, L., & Reddi, H. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3584 · Cited by 215
EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations
Thunnissen, E., Bubendorf, L., Dietel, M., Elmberger, G., Kerr, K., Lopez-Rios, F., Moch, H., Olszewski, W., Pauwels, P., Penault-Llorca, F., et al. (2012) · Virchows Archiv · doi:10.1007/s00428-012-1281-4 · Cited by 212
Smith, R. A., Cokkinides, V., & Brawley, O. W. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20143 · Cited by 203
Brose, M. S., Worden, F. P., Newbold, K. L., Guo, M. D., & Hurria, A. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.6472 · Cited by 200
Diagnosis and management of drug hypersensitivity reactions
Romano, A., Torres, M. J., Castells, M., Sanz, M. L., & Blanca, M. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.11.047 · Cited by 199
Nivolumab: Targeting PD-1 to Bolster Antitumor Immunity
Brahmer, J. R., Hammers, H., & Lipson, E. J. (2015) · Future Oncology · doi:10.2217/fon.15.52 · Cited by 199
Kim, K. B., Cabanillas, M. E., Lazar, A. J., Williams, M. D., Sanders, D. L., Ilagan, J. L., Nolop, K., Lee, R. J., & Sherman, S. I. (2013) · Thyroid · doi:10.1089/thy.2013.0057 · Cited by 197
Killelea, B. K., Yang, V. Q., Mougalian, S., Horowitz, N. R., Pusztai, L., Chagpar, A. B., & Lannin, D. R. (2015) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2015.02.011 · Cited by 197
Wenzel, L. B., Huang, H. Q., Armstrong, D. K., Walker, J. L., & Cella, D. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.3494 · Cited by 197
Assessing Lead Time of Selected Ovarian Cancer Biomarkers: A Nested Case–Control Study
Anderson, G. L., McIntosh, M., Wu, L., Barnett, M., Goodman, G., Thorpe, J. D., Bergan, L., Thornquist, M. D., Scholler, N., Kim, N., et al. (2010) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp438 · Cited by 197
Cabanillas, M. E., Waguespack, S. G., Bronstein, Y., Williams, M. D., Feng, L., Hernandez, M., Lopez, A., Sherman, S. I., & Busaidy, N. L. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1923 · Cited by 194
Brierley, J., Tsang, R., Panzarella, T., & Bana, N. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2005.02358.x · Cited by 189
Basolo, F., Torregrossa, L., Giannini, R., Miccoli, M., Lupi, C., Sensi, E., Berti, P., Elisei, R., Vitti, P., Baggiani, A., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0337 · Cited by 182
Molina, R., Escudero, J. M., Augé, J. M., Filella, X., Foj, L., Torné, A., Lejarcegui, J., & Pahisa, J. (2011) · Tumor Biology · doi:10.1007/s13277-011-0204-3 · Cited by 179
Masuda, N., Sagara, Y., Kinoshita, T., Iwata, H., Nakamura, S., Yanagita, Y., Nishimura, R., Iwase, H., Kamigaki, S., Takei, H., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70373-4 · Cited by 179
BRAF V600E Inhibition in Anaplastic Thyroid Cancer
Rosove, M. H., Peddi, P. F., & Glaspy, J. A. (2013) · New England Journal of Medicine · doi:10.1056/nejmc1215697 · Cited by 179
Osta, B. E., Palmer, J. L., Paraskevopoulos, T., Pei, B.-L., Roberts, L. E., Poulter, V. A., Chacko, R., & Bruera, E. (2008) · Journal of Palliative Medicine · doi:10.1089/jpm.2007.0103 · Cited by 177
Cohn, D. E., Kim, K. H., Resnick, K. E., O'Malley, D. M., & Straughn, J. M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.1075 · Cited by 172
Thyroid Aspiration Cytology: Current Status
Layfield, L. J., Cibas, E. S., Gharib, H., & Mandel, S. J. (2009) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20014 · Cited by 171
(GETC), A. T. G. D. D. T. A. C., Schlumberger, M., Abdelmoumene, N., Delisle, M., & Couette, J. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.73 · Cited by 167
Releasing the Brakes on Cancer Immunotherapy
Littman, D. R. (2015) · Cell · doi:10.1016/j.cell.2015.08.038 · Cited by 166
Almack, K., Cox, K., Moghaddam, N., Pollock, K., & Seymour, J. (2012) · BMC Palliative Care · doi:10.1186/1472-684x-11-15 · Cited by 166
Wynes, M. W., Sholl, L. M., Dietel, M., Schuuring, E., Tsao, M. S., Yatabe, Y., Tubbs, R. R., & Hirsch, F. R. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000115 · Cited by 164
Nolen, B., Velikokhatnaya, L., Marrangoni, A., De Geest, K., Lomakin, A., Bast, R. C., & Lokshin, A. (2010) · Gynecologic Oncology · doi:10.1016/j.ygyno.2010.02.005 · Cited by 164
Kim, H., Yoo, S.-B., Choe, J.-Y., Paik, J. H., Xu, X., Nitta, H., Zhang, W., Grogan, T. M., Lee, C.-T., Jheon, S., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31821cfc73 · Cited by 163
Aberle, D. R., Abtin, F. G., & Brown, K. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.3110 · Cited by 159
Schwartz, D. L., Lobo, M. J., Ang, K. K., Morrison, W. H., Rosenthal, D. I., Ahamad, A., Evans, D. B., Clayman, G., Sherman, S. I., & Garden, A. S. (2009) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2008.09.023 · Cited by 158
Cited by
First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
Carbone, D. P., Reck, M., Paz-Ares, L., Creelan, B., Horn, L., Steins, M., Felip, E., van den Heuvel, M. M., Ciuleanu, T.-E., Badin, F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613493 · Cited by 2,503
Self-citationAppio, L., Landoni, C., La Targia, M., Bertolli, V., Chiarucci, M., Crovetti, G., Vassenna, E., Serio, G., & Bregni, M. (2017) · Chemotherapy · doi:10.1159/000458147 · Cited by 2,327
Chun, S. G., Hu, C., Choy, H., Komaki, R. U., Timmerman, R. D., Schild, S. E., Bogart, J. A., Dobelbower, M. C., Bosch, W., Galvin, J. M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.1378 · Cited by 746
Self-citationThe current state of the art and future trends in RAS-targeted cancer therapies
Punekar, S. R., Velcheti, V., Neel, B. G., & Wong, K.-K. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00671-9 · Cited by 549
Zhong, W.-Z., Wang, Q., Mao, W.-M., Xu, S.-T., Wu, L., Shen, Y., Liu, Y.-Y., Chen, C., Cheng, Y., Xu, L., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30729-5 · Cited by 529
Metadata
- Authors
- Ettinger, D. S., Wood, D. E., Akerley, W., Bazhenova, L. A., Borghaei, H., Camidge, D. R., Cheney, R. T., Chirieac, L. R., D'Amico, T. A., Dilling, T. J., Dobelbower, M. C., Govindan, R., Hennon, M., Horn, L., Jahan, T. M., Komaki, R., Lackner, R. P., Lanuti, M., Lilenbaum, R., Lin, J., Loo, B. W., Martins, R., Otterson, G. A., Patel, J. D., Pisters, K. M., Reckamp, K., Riely, G. J., Schild, S. E., Shapiro, T. A., Sharma, N., Stevenson, J., Swanson, S. J., Tauer, K., Yang, S. C., Gregory, K., & Hughes, M.
- Venue
- Journal of the National Comprehensive Cancer Network
- Publisher
- Harborside Press, LLC
- Published
- 2016-03
- Volume
- 14
- Issue
- 3
- Pages
- 255-264
- ISSN
- 1540-1405 (ISSN-L)
- 1540-1413
- OpenAlex
- W2296139876
- Cited by
- 736
- References
- 306
- FWCI
- 74.68
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.